110TH CONGRESS

1ST SESSION S. 30

AN ACT

To intensify research to derive human pluripotent stem cell

lines.

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled,

3 SECTION 1. SHORT TITLE.

4 This Act may be cited as the ‘‘Hope Offered through

5 Principled and Ethical Stem Cell Research Act’’ or the

6 ‘‘HOPE Act’’.
 †

2

S 30 ES

1 SEC. 2. PURPOSES.

2 It is the purpose of this Act to—

3 (1) intensify research that may result in im4 proved understanding of or treatments for diseases

5 and other adverse health conditions; and

6 (2) promote the derivation of pluripotent stem

7 cell lines without the creation of human embryos for

8 research purposes and without the destruction or

9 discarding of, or risk of injury to, a human embryo

10 or embryos other than those that are naturally dead.

11 SEC. 3. HUMAN PLURIPOTENT STEM CELL RESEARCH.

12 Part H of title IV of the Public Health Service Act

13 (42 U.S.C. 289 et seq.) is amended by inserting after sec14 tion 498C the following:

15 ‘‘SEC. 498D. HUMAN PLURIPOTENT STEM CELL RESEARCH.

16 ‘‘(a) IN GENERAL.—The Secretary shall conduct and

17 support basic and applied research to develop techniques

18 for the isolation, derivation, production, or testing of stem

19 cells, including pluripotent stem cells that have the flexi20 bility of embryonic stem cells (whether or not they have

21 an embryonic source), that may result in improved under22 standing of or treatments for diseases and other adverse

23 health conditions, provided that the isolation, derivation,

24 production, or testing of such cells will not involve—

25 ‘‘(1) the creation of a human embryo or em26 bryos for research purposes; or
†

3

S 30 ES

1 ‘‘(2) the destruction or discarding of, or risk of

2 injury to, a human embryo or embryos other than

3 those that are naturally dead.

4 ‘‘(b) GUIDELINES.—Not later than 90 days after the

5 date of the enactment of this section, the Secretary, after

6 consultation with the Director of NIH, shall issue final

7 guidelines that—

8 ‘‘(1) provide guidance concerning the next steps

9 required for additional research, which shall include

10 a determination of the extent to which specific tech11 niques may require additional animal research to en12 sure that any research involving human cells using

13 these techniques would clearly be consistent with the

14 standards established under subsection (a);

15 ‘‘(2) prioritize research with the greatest poten16 tial for near-term clinical benefit;

17 ‘‘(3) consistent with standards established

18 under subsection (a), take into account techniques

19 outlined by the President’s Council on Bioethics and

20 any other appropriate techniques and research; and

21 ‘‘(4) in the case of research involving stem cells

22 from a naturally dead embryo, require assurances

23 from grant applicants that no alteration of the tim24 ing, methods, or procedures used to create, main25 tain, or intervene in the development of a human
†

4

S 30 ES

1 embryo was made solely for the purpose of deriving

2 the stem cells.

3 ‘‘(c) REPORTING REQUIREMENTS.—Not later than

4 January 1 of each year, the Secretary shall prepare and

5 submit to the appropriate committees of the Congress a

6 report describing the activities carried out under this sec7 tion during the fiscal year, including a description of the

8 research conducted under this section.

9 ‘‘(d) RULE OF CONSTRUCTION.—Nothing in this sec10 tion shall be construed as altering the policy in effect on

11 the date of enactment of this section regarding the eligi12 bility of stem cell lines for funding by the National Insti13 tutes of Health.

14 ‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There

15 is authorized to be appropriated such sums as may be nec16 essary to carry out this section.

17 ‘‘(f) DEFINITIONS.—In this section:

18 ‘‘(1) NATURALLY DEAD.—The term ‘naturally

19 dead’ means having naturally and irreversibly lost

20 the capacity for integrated cellular division, growth,

21 and differentiation that is characteristic of an orga22 nism, even if some cells of the former organism may

23 be alive in a disorganized state.

24 ‘‘(2) HUMAN EMBRYO OR EMBRYOS.—The term

25 ‘human embryo or embryos’ includes any organism,
†

5

S 30 ES

1 not protected as a human subject under part 46 of

2 title 45, Code of Federal Regulations, as of the date

3 of enactment of this section, that is derived by fer4 tilization, parthenogenesis, cloning, or any other

5 means from one or more human gametes or human

6 diploid cells.

7 ‘‘(3) RISK OF INJURY.—The term ‘risk of in8 jury’ means subjecting a human embryo or embryos

9 to risk of injury or death greater than that allowed

10 for research on fetuses in utero under section

11 46.204(b) of title 45, Code of Federal Regulations,

12 and section 498(b) of this Act.’’.

13 SEC. 4. NATIONAL AMNIOTIC AND PLACENTAL STEM CELL

14 BANK.

15 (a) IN GENERAL.—The Secretary of Health and

16 Human Services shall enter into a contract with the Insti17 tute of Medicine for the conduct of a study to recommend

18 an optimal structure for an amniotic and placental stem

19 cell bank program and to address pertinent issues to maxi20 mize the potential of such technology, including collection,

21 storage, standards setting, information sharing, distribu22 tion, reimbursement, research, and outcome measures. In

23 conducting such study, the Institute should receive input

24 from relevant experts including the existing operators of
†

6

S 30 ES

1 federal tissue bank programs and the biomedical research

2 programs within the Department of Defense.

3 (b) REPORT.—Not later than 180 days after the date

4 of enactment of this Act, the Institute of Medicine shall

5 complete the study under subsection (a) and submit to the

6 Secretary of Health and Human Services and the appro7 priate committees of Congress a report on the results of

8 such study.

Passed the Senate April 11, 2007.

Attest:

Secretary.
110TH CONGRESS

1ST SESSION S. 30

AN ACT

To intensify research to derive human pluripotent

stem cell lines.